A recent study shows that cancer cells work together with surrounding healthy cells to build new blood vessels, promoting tumor growth. Researchers found that collagen production is increased by a specific type of transfer RNA, allowing tumors to acquire the necessary resources to grow and spread.
A combination of palbociclib and fulvestrant delays cancer growth in around two thirds of women with advanced hormone-receptor-positive, HER2-negative breast cancer. The treatment allowed many patients to delay the start of chemotherapy.
A new test analyzing cell diversity in tumors can predict survival chances in high-grade breast cancer. The Ecosystem Diversity Index identified aggressive subgroups of breast cancer and was a stronger predictor of survival than established markers.
A new study uses natural laws to predict how cancers evolve over time, potentially leading to personalized treatment. The research suggests that doctors could use mathematical formulas to anticipate a cancer's growth and development, enabling them to choose the most effective treatments.
A new imaging test has been developed to identify more dangerous tumours before they spread, and tailor treatment accordingly. The test uses oxygen-enhanced MRI technology to map areas of oxygen deprivation within tumours.
Scientists discovered a 'master switch' in cancer cells that allows them to survive stress conditions by overriding the normal stress response. The Brf2 protein acts as a sensor and regulates gene activity, enabling cancer cells to thrive under stress.
A new blood test can detect when breast cancers become resistant to standard hormone treatment, allowing for early identification and alternative treatment options. Researchers developed the test to identify ESR1 mutations, which convey resistance to hormone treatment.
Researchers have discovered a new genetic cause of childhood kidney cancer, Wilms tumour, linked to mutations in the REST gene. The study found that REST mutations occur in about 10% of familial cases and can be detected through simple blood tests, providing valuable information for families affected by the disease.
Researchers have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug. The test predicts which patients will not respond to treatment and can inform personalized treatment options.
A new clinical trial has shown that a gene-targeted drug, olaparib, can benefit up to 33% of patients with treatment-resistant advanced prostate cancer. The trial found that men whose tumours had defects in DNA repair machinery responded particularly well to the drug.
A new study of over 25,000 men has identified four new genetic variants associated with an increased risk of testicular cancer. Testing for these variants combined with existing knowledge has revealed that men in the top one per cent of genetic risk have a ten-fold elevated risk of developing testicular cancer.
Scientists have created a highly specific chemical probe that switches off two important proteins implicated in cancer cell proliferation. The probe, CCT251545, selectively binds to CDK8 and CDK19, blocking the WNT signalling pathway and providing new insights into their role in driving cancer growth.
A new test predicts whether breast cancer will spread to the brain by analyzing high activity in a particular gene called alpha beta-crystallin. Women with aggressive forms of breast cancer are three times more likely to develop secondary brain tumors if they test positive.
Scientists developed a test to identify patients at risk of relapse from non-seminomatous germ cell tumour. The test assessed three features: CXCL12 levels, cancer stem cells, and blood vessel presence. It divided patients into three risk groups, with the low-risk group experiencing high relapse-free survival rates.
A new five-gene signature, MG5, identifies high-risk children with aggressive forms of the disease, suggesting personalized treatment options. The test has been validated in samples from 68 patients and could lead to improved survival rates and reduced side effects.
Researchers identified four consensus molecular subtypes of bowel cancer, allowing doctors to treat each type differently. The study has implications for identifying patients at risk of developing more serious disease and tailoring treatments.
A recent study has discovered five new genetic variants associated with brain cancer, including one that increases the risk of glioblastoma by nearly a quarter. These findings provide important clues for developing new treatments against the disease and offer hope for personalized medicine in the future.
A major clinical trial reports that hormone replacement therapy (HRT) is safe and may improve survival chances in women with epithelial ovarian cancer. The study followed 150 women with the common type of ovarian cancer and found that HRT did not reduce overall survival, but rather increased it.
A new study reveals that nearly half of testicular cancer risk comes from inherited genetic faults, significantly higher than in most other cancer types. The research suggests testing for specific genetic variants could help identify patients at substantially increased risk and potentially lead to prevention methods.
Researchers have developed a blood test that can identify patients at risk of breast cancer relapse months before visible signs appear. The test detects cancer DNA in the bloodstream, allowing for early intervention and personalized treatment.
A new genetic test identified nine key genes that can predict which myeloma patients are at risk of developing aggressive disease, leading to the development of personalized treatment plans. The test shows promise in identifying patients who may benefit from intensive treatment and improving survival rates.
A major study of over 30,000 women shows that aromatase inhibitors substantially reduce the risk of death from ER-positive breast cancer. Taking aromatase inhibitors for five years reduces the risk of death by 40% compared to tamoxifen.
Researchers have developed a new drug, CCT245737, that blocks cancer's escape route from chemotherapy, boosting its effectiveness in treating lung and pancreatic cancers. The drug, a CHK1 inhibitor, demonstrates significant anti-cancer activity when combined with chemotherapy in mice.
A new website, the Chemical Probes Portal, aims to guide researchers in selecting better-quality chemical probes, reducing errors and wasting time and money. The platform crowdsources knowledge from leading researchers, providing up-to-date comparative information to help users choose the best probe for their needs.
Researchers use electron cryo-microscopy to visualize proteasome complex in unprecedented detail, revealing target sites for potential cancer drugs. The study paves the way for more precise and effective treatments.
Researchers have discovered a gene mutation associated with an aggressive form of brain cancer called anaplastic oligodendroglioma. The study found that errors in the TCF12 gene render the protein less able to bind to DNA, leading to reduced activity of other key genes, including CHD1.
A genetically engineered herpes virus has been shown to halt the progression of skin cancer by killing cancer cells and sparking an immune system response against tumours. The trial involved 436 patients and showed a durable treatment response in 16.3% of patients, with responses extending past three years.
A comprehensive map of genetic mutations in advanced prostate cancers has been created, revealing that nearly 90% of patients have actionable mutations. This breakthrough could lead to targeted treatments and improve patient outcomes.
A phase I clinical trial has begun for a new 'resistance-busting' experimental skin cancer drug, administered to the first patient just three months after a major publication described its potential. The trial aims to establish the safe maximum dose for a planned phase II clinical trial, focusing on advanced melanoma patients.
A major trial has shown that olaparib can effectively treat advanced prostate cancer in men with defects in DNA repair genes. The results suggest that up to 30% of patients with terminal prostate cancer may benefit from the drug, which could become a treatment option if replication is confirmed in further trials.
A test for 77 genetic risk factors showed a significant link between a woman's polygenic risk score and her breast cancer risk, with those in the top 20% being 1.8 times more likely to develop breast cancer than average women.
Researchers have discovered a new function for the retinoblastoma gene, which plays a central role in stopping healthy cells from dividing uncontrollably. The gene also helps to mend broken strands of DNA by forming clusters with other proteins, opening up new approaches to cancer treatment.
A new study reveals a blood test that measures circulating tumour cells can predict which men are benefitting least from prostate cancer drug treatment after just 12 weeks. The test may allow doctors to switch patients to alternative treatments earlier, speeding up clinical trials and improving survival rates.
A pioneering class of drugs targeting BRCA breast cancer genes may also work against tumours with CLBC gene defects. Researchers found that CLBC-defective cancer cells are vulnerable to PARP inhibitor drugs, opening up new treatment possibilities for a broader group of patients.
A study by the Institute of Cancer Research found that breast cancer cells with a 'mesenchymal-like' shape are more sensitive to inflammatory signals, which could be harnessed to treat cancer. The researchers used robotic microscopy and automated algorithms to measure the shape of hundreds of thousands of different breast cancer cells.
Researchers developed a test to identify women with triple-negative breast cancer, a form of disease difficult to treat. The test assesses gene activity in breast cancer cells, finding those resembling adult stem cells are more likely to spread and recur.
Researchers developed a new test analyzing 'immune hotspots' to predict breast cancer survival. The test uses statistical software to track the immune system's reaction to tumors, identifying those who need intensive treatment.
Research reveals that DNA sequences in 'gene deserts' can regulate gene activity elsewhere by forming DNA loops, increasing cancer risk through wormhole-like effects. The study provides new insights into the role of long-range genetic regulation in cancer development.
Two major studies strengthen the case for abiraterone as a treatment option for men with advanced prostate cancer. The trials found that receiving abiraterone before chemotherapy significantly extended men's lives by an average of four months, compared to those who did not receive it.
A worldwide study of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer. The variants are specifically linked to the most common form of breast cancer, oestrogen receptor positive, providing important clues about its causes and potential leads for treatment discovery.
Researchers identified a genetic mutation that may contribute to tumours becoming resistant to current treatments. The study also found a link between defective copies of the DNA repair gene XRCC2 and platinum-based chemotherapy resistance.
Researchers found that up to a quarter of patients with bowel cancer who have a family history could have their cancer caused by genetic mutations identified through gene testing. This could lead to improved diagnosis, treatment, and early detection for both the patient and their relatives.
A study using mathematical models shows that genetic testing can substantially improve breast cancer prevention by analyzing multiple gene variants. The research suggests that combining genetic data with other risk factors can identify the most at-risk women, who account for 32.2% of all breast cancer cases.
A major new study shows that some prostate cancer treatments can stop working over time and even drive tumour growth. Researchers identified a 'treatment paradigm' using repeated blood samples to monitor signs of therapy becoming counter-productive.
A major international study identified 23 new genetic variants associated with increased risk of prostate cancer, explaining a third of the inherited risk. Testing for these variants can identify 1% of men with a risk almost six times as high as the population average.
Researchers estimated the risk of premature menopause in women treated for Hodgkin lymphoma, providing precise estimates based on treatment types and ages. The study found that certain treatments, such as ovarian radiotherapy and chemotherapy, significantly increased the risk of early menopause.
Researchers found mutations in the CTR9 gene in six children with Wilms tumour, a common kidney cancer in kids, and discovered that malfunctioning PAF1 complex is likely to cause cancer. The study's findings offer hope for improved treatments and screening for affected families.
Researchers tested genetically engineered virus alongside isolated limb perfusion chemotherapy, finding it more effective in rats than either treatment alone. The combination slowed tumour growth and prolonged survival by 50%, offering hope for avoiding amputation and improving quality of life.
A study found that smokers with the BRCA2 gene defect are at an increased risk of developing lung cancer, with around one in four suffering from the disease. The researchers also discovered a link between squamous cell lung cancer and a defect in the CHEK2 gene.
Scientists have identified a genetic variant associated with a higher risk of invasive lobular carcinoma, a type of breast cancer often missed by screening. The study, involving over 6,500 women, found that the variant increases the risk of this cancer by up to 13%.